Yuhao Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yuhao Shi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Brianna M. Jones
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
1 shared publication - Daniel R. Dickstein
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York
1 shared publication - Eric J. Lehrer
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
1 shared publication - Juliana Runnels
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
1 shared publication - Julie Rachel Bloom
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
1 shared publication - Kristin Hsieh
New York Proton Center, New York, NY 10035, USA
1 shared publication
Latest Publications
- Open Access
- 25 July 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (8) , 2097
Combining Radiotherapy and Immunotherapy in Head and Neck Cancer
Head and neck squamous cell carcinoma (HNSCC) is a leading cause of morbidity and mortality globally. Despite significant advances in well-established treatment techniques, prognosis for advanced-stage HNSCC remains poor. Recent, accumulating evidence supports a role for immunotherapy in HNSCC treatment. Radiation therapy (RT), a standard treatment option for HNSCC, has immunomodulatory and immunostimulatory effects that may enhance the efficacy of immunotherapy. In several cancer types, combining RT and immunotherapy has been shown to improve tumor response rates, increase survival, and reduce toxicity compared to traditional chemotherapy and radiation therapy. This review provides a timely overview of the current knowledge on the use of RT and immunotherapy for treating HNSCC. It highlights the potential advantages of combining these therapies, such as improved tumor response rates, increased survival, and reduced toxicity. The review also discusses the challenges that need to be addressed when redefining the standard of care in HNSCC, and proposes further research to optimize treatment combinations, minimize radiation-induced toxicity, and identify suitable patient populations for treatment.
- 25 July 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (8) , 2097
Open AccessCombining Radiotherapy and Immunotherapy in Head and Neck Cancer
Head and neck squamous cell carcinoma (HNSCC) is a leading cause of morbidity and mortality globally. Despite significant advances in well-established treatment techniques, prognosis for advanced-stage HNSCC remains poor. Recent, accumulating evidence supports a role for immunotherapy in HNSCC treatment. Radiation therapy (RT), a standard treatment option for HNSCC, has immunomodulatory and immunostimulatory effects that may enhance the efficacy of immunotherapy. In several cancer types, combining RT and immunotherapy has been shown to improve tumor response rates, increase survival, and reduce toxicity compared to traditional chemotherapy and radiation therapy. This review provides a timely overview of the current knowledge on the use of RT and immunotherapy for treating HNSCC. It highlights the potential advantages of combining these therapies, such as improved tumor response rates, increased survival, and reduced toxicity. The review also discusses the challenges that need to be addressed when redefining the standard of care in HNSCC, and proposes further research to optimize treatment combinations, minimize radiation-induced toxicity, and identify suitable patient populations for treatment.